Four Years’ Experience with the Edwards-Tekna Bileaflet Valve Prosthesis
Tanzer Calkavur MD, Tahir Yagdi MD, Anil Apaydin MD, Fatih Islamoglu MD,
Hakan Posacioglu MD, Isa Durmaz MD, Mustafa Özbaran MD

This report outlines short-term results with the revised Edwards-Tekna valve. A total of 137 patients (67 males, 70 females; mean age 36.3 ± 9.1 years) underwent mechanical valve replacement with an Edwards-Tekna prosthesis. Early hospital mortality was 0.72% (n = 1). Actuarial freedom from complications at two years follow up and linearized incidence (%/patient-year (pt-yr)) of these events were: late mortality 87.8 ± 8.5% (1.77%/pt-yr); thromboembolism 89.8 ± 4.9% (2.12%/pt-yr); anticoagulation-related bleeding 97.8 ± 1.5% (0.71%/pt-yr); prosthetic valve endocarditis 99.1 ± 0.9% (0.35%/pt-yr); valve-related mortality 98.2 ± 1.2% (0.71%/pt-yr); and valve-related morbidity and mortality 85.0 ± 5.0% (4.24%/pt-yr). There was no structural valve failure such as leaflet escape in this series. The Edwards-Tekna mechanical valve prosthesis has shown excellent overall clinical performance during the short-term.